Literature DB >> 18761720

The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis.

C J Boos1, B Balakrishnan, A D Blann, G Y H Lip.   

Abstract

BACKGROUND: While coronary artery disease has been linked to both endothelial damage and cellular apoptosis, their inter-relationships and impact on cardiovascular (CV) outcomes has been barely explored. AIMS: First, we investigated the inter-relationships between circulating endothelial cells (CECs, and index of endothelial damage) and circulating plasma markers of endothelial damage/dysfunction [von Willebrand factor (VWF), soluble E selectin (sEsel)] and apoptosis [soluble Fas (sFas), Fas ligand (sFasL) and their ratio, sFas/sFasL] in patients presenting with acute coronary syndrome (ACS). Second, we assessed their prognostic values for major adverse CV events (MACE) in ACS.
METHODS: We studied 211 patients with ACS, who were compared with 60 healthy controls (HC) and 45 'disease controls' (patients with stable coronary artery disease, CAD). Simultaneous blood samples for CECs (immunobead method), VWF, sESel, sFas and sFasL (ELISA) were taken within 24 h of presentation of ACS and at 48 h post admission.
RESULTS: CEC, sEsel and VWF levels were significantly higher among the ACS groups compared with the CAD and HC (P < 0.05) groups. sFas was higher (P = 0.016) and sFasL lower (P = 0.021) in ACS compared with controls (HC and CAD). There was a significant increase in sFas/sFasL ratio with increasing disease severity (P = 0.0004). There were significant correlations between CECs and both VWF and sEsel (both P < 0.01) but no correlations between CECs and either sFas or sFas ligand. On univariate survival analysis, CECs were associated with an increased risk of both MACE [hazard ratio (HR) 2.4 (95% CI 1.2-4.1); P = 0.009] and cardiovascular death [HR 2.95 (95% CI 1.01-8.81); P = 0.047]. On multivariate Cox regression analysis, only VWF (and not CECs) remained as an independent predictor of MACE [HR 1.02 (95% CI 1.005-1.040); P = 0.009].
CONCLUSION: CECs were associated with abnormal plasma indices of endothelial damage/dysfunction and not apoptosis, despite abnormalities of all these markers being associated with ACS. VWF remained as an independent predictor of MACE, on multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761720     DOI: 10.1111/j.1538-7836.2008.03148.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  10 in total

1.  Comparison of endothelial biomarkers according to reversibility of pulmonary hypertension secondary to congenital heart disease.

Authors:  David M Smadja; Pascale Gaussem; Laetitia Mauge; Romaric Lacroix; Sophie Gandrille; Véronique Remones; Séverine Peyrard; Florence Sabatier; Damien Bonnet; Marilyne Lévy
Journal:  Pediatr Cardiol       Date:  2010-02-27       Impact factor: 1.655

2.  Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index.

Authors:  Patrick K Y Goon; Gregory Y H Lip; Paul S Stonelake; Andrew D Blann
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

3.  Peculiarities of Immune Regulation in Men of Perm Region with Atherosclerosis Related to Polymorphism of Candidate Genes.

Authors:  N A Nikonoshina; N V Zaitseva; О V Dolgikh
Journal:  Bull Exp Biol Med       Date:  2021-03-31       Impact factor: 0.804

4.  Circulating endothelial cells in patients with venous thromboembolism and myeloproliferative neoplasms.

Authors:  Cláudia Torres; Ana Mafalda Fonseca; Magdalena Leander; Rui Matos; Sara Morais; Manuel Campos; Margarida Lima
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

5.  The Relationship between Endothelial Dysfunction and Endothelial Cell Markers in Peripheral Arterial Disease.

Authors:  Kimihiro Igari; Toshifumi Kudo; Takahiro Toyofuku; Yoshinori Inoue
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

6.  Enumeration of circulating endothelial cell frequency as a diagnostic marker in aortic valve surgery - a flow cytometric approach.

Authors:  Anton Sabashnikov; Klaus Neef; Vera Chesnokova; Leonie Wegener; Kathrin Godthardt; Maximilian Scherner; Elmar W Kuhn; Antje-Christin Deppe; Meike Lauer; Kaveh Eghbalzadeh; Mohamed Zeriouh; Parwis B Rahmanian; Jens Wippermann; Ferdinand Kuhn-Régnier; Navid Madershahian; Thorsten Wahlers; Alexander Weymann; Yeong-Hoon Choi
Journal:  J Cardiothorac Surg       Date:  2017-08-09       Impact factor: 1.637

7.  A Whole Blood Molecular Signature for Acute Myocardial Infarction.

Authors:  Evan D Muse; Eric R Kramer; Haiying Wang; Paddy Barrett; Fereshteh Parviz; Mark A Novotny; Roger S Lasken; Timothy A Jatkoe; Glenn Oliveira; Hongfan Peng; Jerry Lu; Mark C Connelly; Kurt Schilling; Chandra Rao; Ali Torkamani; Eric J Topol
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

8.  Endothelial progenitor cells in chronic obstructive pulmonary disease and emphysema.

Authors:  Margaret F Doyle; Russell P Tracy; Megha A Parikh; Eric A Hoffman; Daichi Shimbo; John H M Austin; Benjamin M Smith; Katja Hueper; Jens Vogel-Claussen; Joao Lima; Antoinette Gomes; Karol Watson; Steven Kawut; R Graham Barr
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

9.  Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events: a systematic review and meta-analysis.

Authors:  Mengge Fan; Xia Wang; Xun Peng; Shuo Feng; Junyu Zhao; Lin Liao; Yong Zhang; Yinglong Hou; Ju Liu
Journal:  BMC Cardiovasc Disord       Date:  2020-02-10       Impact factor: 2.298

10.  Generation of a Novel In Vitro Model to Study Endothelial Dysfunction from Atherothrombotic Specimens.

Authors:  Nicholas L Mills; Olga Tura-Ceide; Susan Gallogly; Takeshi Fujisawa; John D Hung; Mairi Brittan; Elizabeth M Skinner; Andrew J Mitchell; Claire Medine; Neus Luque; Erika Zodda; Marta Cascante; Patrick W Hadoke
Journal:  Cardiovasc Drugs Ther       Date:  2021-02-20       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.